Aktuellt
SENASTE
Redeye maintains its valuation and positive view on Orexo after the Q4 report. Increased investments in R&D and the new amorphOX drug delivery platform strengthen the company's innovation capabilities and future prospects. While we expect near-term negative cashflow, we are positive for the mid- and long-term prospects of Orexo in both pharma and digital therapies.
LÄS MER
